Sun Pharma offer too low: Mark Mobius
When Mark Mobius, Executive Chairman, Franklin Templeton, speaks fund managers across the world sit up and take notice. But his plain speaking on Friday may just bring a new twist to the Sun Pharma-Taro tussle, a twist that can potentially change the game from here on. Speaking to NDTV Profit, emerging market guru Mark Mobius defended Taro's decision to terminate the deal as he called the Sun Pharma offer too low and unattractive.
